Research
By the Numbers
1 ST
U.S. Pharm.D. Program
U.S. News World & Report
2 ND
Among Schools of Pharmacy in NIH and Total Research Funding
3 RD
Among Schools of Pharmacy, Best World Universities in Pharmacy and Pharmacology
2024 QS World University Rankings
7 TH
Best World Universities in Pharmacy and Pharmacology
2024 QS World University Rankings
Our Research Enterprise
We are organized based on the drug development, delivery and patient care cycle.
Drug Optimization
Discover and evaluate the factors that influence how therapeutic agents work
Patient Outcomes
Identify the health outcomes and value of therapies, policies and practices
A Culture of Collaboration
Partnering across the campus, state, nation and around the world to advance research, education and practice.
UNC Health Sciences Campus
The School is part of the University of North Carolina at Chapel Hill, a major research university with a large teaching hospital and schools of medicine, public health, nursing, and dentistry.
- Ranked 5th nationally for federal research among all universities
- $1.1 billion in sponsored research from all sources annually
- Eleventh largest research university in research volume and annual expenditures
Institute for Convergent Science
The UNC Institute for Convergent Science (ICS) brings multidisciplinary teams together from the College of Arts & Sciences, Eshelman School of Pharmacy, Gillings School of Global Public Health, the School of Medicine and UNC Lineberger Comprehensive Cancer Center to break down the barriers to new discoveries by finding the most direct path to solving the world’s greatest problems.
Located in Carolina’s premier science research facility, the UNC Genome Sciences Building, ICS brings the very best commercialization process to the University’s more than $1.15 billion research enterprise.
Eshelman Innovation
Eshelman Innovation is a health care innovation engine that bridges the inspiration of academia and the spirit of entrepreneurship to turn groundbreaking ideas into real products and services. They are here to catalyze ideas for the greater good. Since its creation in 2014, Eshelman Innovation has expanded well beyond the walls of the school of pharmacy at UNC-Chapel Hill. Eshelman Innovation works with faculty across the state and collaborators around the world. Their work brings together academic firepower alongside funders and donors to find creative solutions to major health care problems.
Partnership in Patient Care
The Partnership in Patient Care combines the resources of the School and the UNC Medical Center pharmacy department to increase the pharmacy services available to patients at UNC Hospitals, the amount of experiential education that pharmacy students receive at the UNC Eshelman School of Pharmacy and the amount of point-of-care research being conducted.
Research Triangle Park
UNC anchors one corner of North Carolina’s famed Research Triangle Park, which hosts an abundance of pharmaceutical, biotech, and health-care companies. This environment offers many opportunities for collaboration in research, education, and patient care with partners in academia, industry, and health care.
Pinnacle Hill
The University of North Carolina at Chapel Hill and Deerfield Management have entered into a partnership to create Pinnacle Hill, a company seeking to discover new medicines to address the significant unmet medical needs of our times. Deerfield will invest up to $65 million of targeted funding through Pinnacle Hill, as well as providing significant drug development expertise to advance promising therapeutic research at UNC-Chapel Hill. Learn more here.
PharmAlliance
PharmAlliance is a unique international partnership between three global leaders in pharmacy education, the University of North Carolina at Chapel Hill, Monash University, and University College London. PharmAlliance partners work collaboratively to inspire and train tomorrow’s professional leaders and practitioners to transform education delivery and address major research challenges in pharmacy and the pharmaceutical sciences.
Structural Genomics Consortium
The SGC (Structural Genomics Consortium) is a not-for-profit, public-private partnership that performs basic science of relevance to drug discovery. Research is conducted at several sites around the world to produce reagents, proteins, antibodies, assays, and data that support exploration of the human genome. All material and intellectual output of the SGC is placed in the public domain for use without restriction. The first SGC laboratory to operate in the USA is located in the UNC Eshelman School of Pharmacy. Learn more here.
READDI
Rapidly Emerging Antiviral Drug Discovery Initiative (READDI) is a partnership between the Structural Genomics Consortium (SGC), the University of North Carolina at Chapel Hill and the Eshelman Institute for Innovation aimed at discovering and developing drugs to put “on the shelf” for clinical trial testing in anticipation of future viral pandemics.
Events
Wednesday 12:20 pm
Next Generation Drug Discovery: Proximity-Based Therapeutics
Wednesday 4:00 pm